findmyKOL

John Volpi, MD

Enriched profile

Associate Professor of Clinical Neurology · Houston Methodist

ORCID↗NPI↗
✓ Full profile
Region🇺🇸 Houston, TX · South Central · United StatesSpecialtyNeurologyFocusAcute Ischemic Stroke Management+4
Active KOLfindmyKOL type: EliteLatest publication2025Online presenceverified 2026Payments2021–2025NIH funding2025–2025

John Volpi is Associate Professor of Clinical Neurology at Houston Methodist. OpenAlex indexes 108 publications with 2,001 citations (h-index 21); ClinicalTrials.gov lists 1 registered study with this person as an investigator.

Data verified 16 Oct 2026

Overview

Updated 22 Oct 2026

John Volpi, MD, is Associate Professor of Clinical Neurology at Houston Methodist. The public record shows 108 publications with 2,001 citations (h-index 21), centered on Acute Ischemic Stroke Management, Cardiovascular and Diving-Related Complications, Intracranial Aneurysms: Treatment and Complications. It also documents an investigator role on 1 registered clinical trials, industry payments reported by 35 companies, 1 NIH-funded awards (2025–2025).

  • Most recent indexed publication: 2025 · Stroke
  • Top research focus: Acute Ischemic Stroke Management
  • 1 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 35 companies

Generated from the cited public record · current as of 22 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Stroke1 trial

Research focus

OpenAlex concept fingerprint
Acute Ischemic Stroke ManagementCardiovascular and Diving-Related ComplicationsIntracranial Aneurysms: Treatment and ComplicationsCerebrovascular and Carotid Artery DiseasesIntracerebral and Subarachnoid Hemorrhage Research

Drugs & molecules

across trials, industry payments and publications
Xareltogeneric · RivaroxabanClinical trials—Industry payments133Publications—Repathageneric · EvolocumabClinical trials—Industry payments63Publications—Eliquisgeneric · ApixabanClinical trials—Industry payments16Publications—Nuedextageneric · Dextromethorphan / quinidineClinical trials—Industry payments14Publications—Andexxageneric · Andexanet alfaClinical trials—Industry payments12Publications—Briviactgeneric · BrivaracetamClinical trials—Industry payments12Publications—RimegepantClinical trials—Industry payments11Publications—Brilintageneric · TicagrelorClinical trials—Industry payments8Publications—Kynmobigeneric · ApomorphineClinical trials—Industry payments5Publications—APTIOMClinical trials—Industry payments3Publications—Camzyosgeneric · MavacamtenClinical trials—Industry payments2Publications—Fabrazymegeneric · Agalsidase betaClinical trials—Industry payments2Publications—

Works with

trial sponsors and companies reporting payments
Janssen Pharmaceuticals, IncClinical trials—Industry payments133Amgen Inc.Clinical trials—Industry payments67W. L. Gore & Associates, Inc.Clinical trials—Industry payments61AstraZeneca Pharmaceuticals LPClinical trials—Industry payments23Siemens Medical Solutions USA, Inc.Clinical trials—Industry payments21Pfizer Inc.Clinical trials—Industry payments14E.R. Squibb & Sons, L.L.C.Clinical trials—Industry payments13UCB, Inc.Clinical trials—Industry payments13Boston Scientific CorporationClinical trials—Industry payments9Sunovion Pharmaceuticals Inc.Clinical trials—Industry payments8Avanir Pharmaceuticals, Inc.Clinical trials—Industry payments7Otsuka America Pharmaceutical, Inc.Clinical trials—Industry payments7Abbvie Inc.Clinical trials—Industry payments4Genentech USA, Inc.Clinical trials—Industry payments4Alexion Pharmaceuticals, Inc.Clinical trials—Industry payments3CSL BehringClinical trials—Industry payments3Novartis Pharmaceuticals CorporationClinical trials—Industry payments3Abbott LaboratoriesClinical trials—Industry payments2Amneal Pharmaceuticals LLCClinical trials—Industry payments2Biogen, Inc.Clinical trials—Industry payments2GE HealthCareClinical trials—Industry payments2Genzyme CorporationClinical trials—Industry payments2Medtronic, Inc.Clinical trials—Industry payments2SK Life Science, Inc.Clinical trials—Industry payments2ACADIA Pharmaceuticals IncClinical trials—Industry payments1Alnylam Pharmaceuticals Inc.Clinical trials—Industry payments1Bayer Healthcare Pharmaceuticals Inc.Clinical trials—Industry payments1Chiesi USA, Inc.Clinical trials—Industry payments1Esperion Therapeutics, Inc.Clinical trials—Industry payments1Microtransponder, Inc.Clinical trials—Industry payments1

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
108publications

Distinct works indexed by OpenAlex, matched via ORCID; 1 in PubMed.

2,001citations

Total citations across indexed works.

21h-index

Hirsch index (OpenAlex). i10-index 31.

Clinical & industry

trials, payments and federal funding
1clinical trials

Investigator role on registered studies.

View trials ↓
35companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
1NIH grants · 2025–2025

Federally funded research awards.

View funding ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 22 Oct 2026

Listed as an investigator on 1 registered study on ClinicalTrials.gov. The most recent:

Industry payments

Updated 22 Oct 2026

35 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    44.8%
    Statin17.8%
    Rosuvastatin Calcium48%Atorvastatin Calcium44%Pravastatin Sodium5%Pitavastatin Calcium3%
    Part D<11 patients
    Cholesterol absorption inhibitor6.6%
    Ezetimibe100%
    Part D≥64 patients

    + 9 more classes in this area

  • Blood & clotting

    32.4%
    Factor Xa inhibitor22.4%
    Xarelto69%Eliquis31%
    Part D≥112 patients
    P2Y12 inhibitor9.6%
    Clopidogrel92%Brilinta8%
    Part D<11 patients

    + 1 more class in this area

  • Nervous system

    22.3%
    Other antiepileptics3.6%
    Levetiracetam62%Lacosamide22%Levetiracetam Er16%
    Part D<11 patients
    Gabapentinoids3.6%
    Gabapentin100%
    Part D≥38 patients

    + 10 more classes in this area

All 4 therapeutic areas: search, sort and filter.Explore →
Where care is delivered (Part B)37.8% facility · 62.2% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 22 Oct 2026

1 NIH research award on record, funded 2025–2025 per NIH RePORTER. The latest:

Publications

Updated 22 Oct 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Network

Updated 22 Oct 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Rajan R. Gadhia22Stephen T.C. Wong21Kelvin Wong16Scott Eric Kasner15Eva A. Mistry15Akshitkumar M. Mistry14Tanu Garg14Farhaan Vahidy13Rohan V Chitale13Christopher D. Streib12Shadi R. Yaghi12Alan P. Pan12Vivek Misra12James Z. Wang12Stephan A. Mayer11Kishan Patel11Amy Kathryn Starosciak11Natasha R Barnhill11Amjad Tarboosh11James Ernest Siegler11Katarina B. Dakay11Salman Assad11Niraj Arora11Mahesh V. Jayaraman11Bharathi Jagadeesan11Felipe De Los Rios La Rosa11Tapan Mehta11Pooja Kumari Khatri11Charles D MCCANE11Xiaolei Huang10Steven Russell Messe10Thomas B. H. Potter10Abdulaziz Tijjani Bako10Stewart A. Weber10David T. W. Chiu10Alicia Bennett10Jonika D Tannous9Heidi J. Sucharew9Jeff Wagner9Ashkan Mowla8

Online presence

Updated 22 Oct 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/john-volpi-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
  • LinkedIn

    linkedin.com/in/john-volpi-05876490

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 22 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →newswise.com ↗
  • Board certified

    Adult Neurology (American Board of Psychiatry and Neurology)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →houstonmethodist.org ↗
  • Board certified

    Neurosonology (American Society of Neuroimaging)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →houstonmethodist.org ↗

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.